A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin ... have sent a letter (PDF) to Novo Nordisk to request more ...

Along with NASH, Novo Nordisk is also planning to investigate the drug's activity in chronic kidney disease and cardiometabolic conditions. She added that VENT-01 has the potential to offer "best ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time. AbbVie's fundamentals ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...